Department of the Army September 13, 2010 – Federal Register Recent Federal Regulation Documents

In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 (a)(1)(i) and 404.7(b)(1)(i), announcement is made of the intent to grant a field of use exclusive, revocable license for the field of prevention and/or therapeutic treatment of vaccinia virus infections or other orthopoxvirus infections to the inventions claimed in U.S. Patent No. 6,451,309 entitled ``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued September 17, 2002, and U.S. Patent No. 6,620,412 entitled ``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued September 16, 2003, which is a continuation of U.S. Patent No. 6,451,309, and related foreign patents and patent applications (PCT/ US2001/04520) to Biofactura, Inc., with its principal place of business at 9430 Key West Avenue, Suite 125, Rockville, MD 20850-6345.